COVIVIO (COV.PA) Fundamental Analysis & Valuation

EPA:COV • FR0000064578

Current stock price

58.7 EUR
-1.45 (-2.41%)
Last:

This COV.PA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. COV.PA Profitability Analysis

1.1 Basic Checks

  • COV had positive earnings in the past year.
  • COV had a positive operating cash flow in the past year.
  • Of the past 5 years COV 4 years were profitable.
  • COV had a positive operating cash flow in each of the past 5 years.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B -1B

1.2 Ratios

  • COV's Return On Assets of 2.92% is in line compared to the rest of the industry. COV outperforms 53.66% of its industry peers.
  • COV has a Return On Equity of 8.58%. This is in the better half of the industry: COV outperforms 73.17% of its industry peers.
  • COV has a Return On Invested Capital (3.19%) which is in line with its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for COV is in line with the industry average of 3.75%.
  • The 3 year average ROIC (3.14%) for COV is below the current ROIC(3.19%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 2.92%
ROE 8.58%
ROIC 3.19%
ROA(3y)-0.83%
ROA(5y)0.61%
ROE(3y)-2.81%
ROE(5y)1.64%
ROIC(3y)3.14%
ROIC(5y)2.87%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10

1.3 Margins

  • COV's Profit Margin of 51.93% is in line compared to the rest of the industry. COV outperforms 56.10% of its industry peers.
  • COV's Profit Margin has improved in the last couple of years.
  • COV has a worse Operating Margin (56.60%) than 60.98% of its industry peers.
  • In the last couple of years the Operating Margin of COV has declined.
  • COV has a Gross Margin (71.88%) which is comparable to the rest of the industry.
  • COV's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 56.6%
PM (TTM) 51.93%
GM 71.88%
OM growth 3Y-4.77%
OM growth 5Y-2.14%
PM growth 3Y-0.58%
PM growth 5Y7.28%
GM growth 3Y-3.29%
GM growth 5Y-2.55%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

1

2. COV.PA Health Analysis

2.1 Basic Checks

  • COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • COV has about the same amout of shares outstanding than it did 1 year ago.
  • The number of shares outstanding for COV has been increased compared to 5 years ago.
  • The debt/assets ratio for COV has remained at the same level compared to a year ago.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • COV has an Altman-Z score of 0.62. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
  • COV has a worse Altman-Z score (0.62) than 78.05% of its industry peers.
  • The Debt to FCF ratio of COV is 45.20, which is on the high side as it means it would take COV, 45.20 years of fcf income to pay off all of its debts.
  • COV's Debt to FCF ratio of 45.20 is on the low side compared to the rest of the industry. COV is outperformed by 68.29% of its industry peers.
  • COV has a Debt/Equity ratio of 1.04. This is a high value indicating a heavy dependency on external financing.
  • COV has a Debt to Equity ratio of 1.04. This is in the lower half of the industry: COV underperforms 75.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF 45.2
Altman-Z 0.62
ROIC/WACC0.55
WACC5.84%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 0.92 indicates that COV may have some problems paying its short term obligations.
  • With a decent Current ratio value of 0.92, COV is doing good in the industry, outperforming 73.17% of the companies in the same industry.
  • COV has a Quick Ratio of 0.92. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of COV (0.78) is better than 63.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.92
Quick Ratio 0.78
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B

5

3. COV.PA Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.26% over the past year.
  • COV shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.44% yearly.
  • The Revenue has grown by 9.31% in the past year. This is quite good.
  • COV shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.64% yearly.
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
Revenue 1Y (TTM)9.31%
Revenue growth 3Y6.59%
Revenue growth 5Y7.64%
Sales Q2Q%40.47%

3.2 Future

  • The Earnings Per Share is expected to grow by 3.56% on average over the next years.
  • COV is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.64% yearly.
EPS Next Y3.92%
EPS Next 2Y3.77%
EPS Next 3Y3.56%
EPS Next 5YN/A
Revenue Next Year4.98%
Revenue Next 2Y5.31%
Revenue Next 3Y9.64%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3 4 5

3

4. COV.PA Valuation Analysis

4.1 Price/Earnings Ratio

  • COV is valuated correctly with a Price/Earnings ratio of 12.36.
  • The rest of the industry has a similar Price/Earnings ratio as COV.
  • When comparing the Price/Earnings ratio of COV to the average of the S&P500 Index (27.89), we can say COV is valued rather cheaply.
  • A Price/Forward Earnings ratio of 11.89 indicates a reasonable valuation of COV.
  • The rest of the industry has a similar Price/Forward Earnings ratio as COV.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 38.50, COV is valued rather cheaply.
Industry RankSector Rank
PE 12.36
Fwd PE 11.89
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of COV is on the same level as its industry peers.
  • COV's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. COV is more expensive than 70.73% of the companies in the same industry.
Industry RankSector Rank
P/FCF 27.3
EV/EBITDA 17.74
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)3.15
PEG (5Y)5.06
EPS Next 2Y3.77%
EPS Next 3Y3.56%

7

5. COV.PA Dividend Analysis

5.1 Amount

  • COV has a Yearly Dividend Yield of 6.45%, which is a nice return.
  • Compared to an average industry Dividend Yield of 5.38, COV pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.45%

5.2 History

  • The dividend of COV is nicely growing with an annual growth rate of 33.77%!
Dividend Growth(5Y)33.77%
Div Incr Years3
Div Non Decr Years3
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • COV pays out 52.47% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The dividend of COV is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP52.47%
EPS Next 2Y3.77%
EPS Next 3Y3.56%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

COV.PA Fundamentals: All Metrics, Ratios and Statistics

COVIVIO

EPA:COV (4/20/2026, 4:51:18 PM)

58.7

-1.45 (-2.41%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-18
Earnings (Next)07-21
Inst Owners40.98%
Inst Owner ChangeN/A
Ins Owners0.41%
Ins Owner ChangeN/A
Market Cap6.55B
Revenue(TTM)1.42B
Net Income(TTM)738.70M
Analysts74.67
Price Target64.17 (9.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.45%
Yearly Dividend3.5
Dividend Growth(5Y)33.77%
DP52.47%
Div Incr Years3
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.17%
PT rev (3m)1.48%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.56%
EPS NY rev (3m)3.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)0.24%
Valuation
Industry RankSector Rank
PE 12.36
Fwd PE 11.89
P/S 4.61
P/FCF 27.3
P/OCF 7.99
P/B 0.76
P/tB 0.79
EV/EBITDA 17.74
EPS(TTM)4.75
EY8.09%
EPS(NY)4.94
Fwd EY8.41%
FCF(TTM)2.15
FCFY3.66%
OCF(TTM)7.34
OCFY12.51%
SpS12.74
BVpS77.17
TBVpS74.08
PEG (NY)3.15
PEG (5Y)5.06
Graham Number90.8185 (54.72%)
Profitability
Industry RankSector Rank
ROA 2.92%
ROE 8.58%
ROCE 3.57%
ROIC 3.19%
ROICexc 3.29%
ROICexgc 3.34%
OM 56.6%
PM (TTM) 51.93%
GM 71.88%
FCFM 16.87%
ROA(3y)-0.83%
ROA(5y)0.61%
ROE(3y)-2.81%
ROE(5y)1.64%
ROIC(3y)3.14%
ROIC(5y)2.87%
ROICexc(3y)3.29%
ROICexc(5y)2.99%
ROICexgc(3y)3.34%
ROICexgc(5y)3.02%
ROCE(3y)3.52%
ROCE(5y)3.21%
ROICexgc growth 3Y7.76%
ROICexgc growth 5Y7.65%
ROICexc growth 3Y7.37%
ROICexc growth 5Y7.44%
OM growth 3Y-4.77%
OM growth 5Y-2.14%
PM growth 3Y-0.58%
PM growth 5Y7.28%
GM growth 3Y-3.29%
GM growth 5Y-2.55%
F-Score7
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF 45.2
Debt/EBITDA 9.43
Cap/Depr 402.5%
Cap/Sales 40.75%
Interest Coverage 250
Cash Conversion 86.36%
Profit Quality 32.49%
Current Ratio 0.92
Quick Ratio 0.78
Altman-Z 0.62
F-Score7
WACC5.84%
ROIC/WACC0.55
Cap/Depr(3y)539.5%
Cap/Depr(5y)657.35%
Cap/Sales(3y)47.55%
Cap/Sales(5y)52.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.26%
EPS 3Y1.22%
EPS 5Y2.44%
EPS Q2Q%6.28%
EPS Next Y3.92%
EPS Next 2Y3.77%
EPS Next 3Y3.56%
EPS Next 5YN/A
Revenue 1Y (TTM)9.31%
Revenue growth 3Y6.59%
Revenue growth 5Y7.64%
Sales Q2Q%40.47%
Revenue Next Year4.98%
Revenue Next 2Y5.31%
Revenue Next 3Y9.64%
Revenue Next 5YN/A
EBIT growth 1Y1.09%
EBIT growth 3Y1.5%
EBIT growth 5Y5.33%
EBIT Next Year7.55%
EBIT Next 3Y6.51%
EBIT Next 5YN/A
FCF growth 1Y-37.6%
FCF growth 3Y22.6%
FCF growth 5YN/A
OCF growth 1Y-16.4%
OCF growth 3Y5.5%
OCF growth 5Y10.36%

COVIVIO / COV.PA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 4 / 10 to COV.PA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 3 / 10 to COVIVIO (COV.PA). This can be considered as Overvalued.


What is the profitability of COV stock?

COVIVIO (COV.PA) has a profitability rating of 5 / 10.


Can you provide the financial health for COV stock?

The financial health rating of COVIVIO (COV.PA) is 1 / 10.


What is the earnings growth outlook for COVIVIO?

The Earnings per Share (EPS) of COVIVIO (COV.PA) is expected to grow by 3.92% in the next year.